Clinical Trials on Urticarial Vasculitis in Switzerland

Total 42 results

University of Zurich

Unknown

Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (NEUTROGENE)

Pustular Psoriasis | Erosive Pustular Dermatosis of the Scalp | Behcet's Disease | Dermatitis Herpetiformis | Pyoderma Gangrenosum | Linear IgA Bullous Dermatosis | Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue | Sweet's Syndrome | Bowel-associated Dermatosis-arthritis Syndrome | Acute Generalized Exanthematous Pustulosis and other conditions

Switzerland
University Hospital Inselspital, Berne
Novartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-AC

Completed

Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

Chronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous Urticaria

Switzerland
University of Zurich

Unknown

Efficacy Study of Canakinumab to Treat Urticaria (URTICANA)

Chronic Idiopathic Urticaria

Switzerland
University Hospital, Basel, Switzerland

Completed

Frequency of Parasite Infestation in Patients With Chronic Spontaneous Urticaria

Parasitic Disease | Chronic Spontaneous Urticaria

Switzerland
Hospices Civils de Lyon

Unknown

CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors

Churg-Strauss Syndrome

Switzerland
Novartis Pharmaceuticals

Completed

Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Intraocular Inflammation | Retinal Vascular Occlusion

Switzerland
Hospices Civils de Lyon

Unknown

CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors

Microscopic Polyangiitis | Polyarteritis Nodosa

Switzerland
University of Zurich

Completed

Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

Livedoid Vasculitis

Switzerland
University Hospital Inselspital, Berne

Completed

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab (GUSTO)

Giant Cell Arteritis

Switzerland
Insel Gruppe AG, University Hospital Bern
Paul Scherrer Institut, Center for Proton Therapy

Not yet recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis (CRAFT)

Giant Cell Arteritis

Switzerland
University Hospital Inselspital, Berne
Roche Pharma AG; University of Bern

Completed

Tocilizumab for Patients With Giant Cell Arteritis

Giant Cell Arteritis

Switzerland
University Hospital, Basel, Switzerland
Novartis; Schweizerische Stiftung für die Erforschung der Muskelkrankheiten

Recruiting

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

Polymyalgia Rheumatica (PMR) | Giant Cell Arteritis (GCA)

Switzerland
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Giant Cell Arteritis

Switzerland
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

Vasculitis | Systemic Lupus Erythematosus (SLE)

Switzerland
University Hospital, Basel, Switzerland

Terminated

Venous Vascularization and Inflammation on Contrast-enhanced Ultrasound (CEUS) in Patients With Thrombosis

Thrombosis

Switzerland
University Hospital, Basel, Switzerland
Swiss Foundation for the Study of Muscular Diseases

Completed

Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course

Giant Cell Arteritis | Large Vessel Giant Cell Arteriitis

Switzerland
ChemoCentryx

Completed

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)

ANCA-Associated Vasculitis

United States, Australia, Belgium, Canada, France, Italy, Japan, Netherlands, Spain, United Kingdom, Austria, Czechia, Denmark, Germany, Hungary, Ireland, New Zealand, Norway, Sweden, Switzerland
Genentech, Inc.

Completed

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Chronic Idiopathic Urticaria

Germany, United Kingdom, United States, Switzerland, Australia, New Zealand, Poland, Singapore
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

Belimumab in Remission of VASculitis (BREVAS)

Vasculitis

United States, Australia, France, Spain, Italy, Peru, Belgium, Canada, Germany, Romania, Mexico, United Kingdom, Hungary, Ireland, Poland, Switzerland, Czechia, Russian Federation, Norway, Sweden
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Argentina, Hungary, Thailand, Turkey, Malaysia, Canada, Bulgaria, Slovakia, Brazil, Poland
InflaRx GmbH

Completed

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (IXchange)

Granulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)

Germany, Russian Federation, Belgium, France, Spain, Czechia, Italy, Netherlands, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Giant Cell Arteritis | Polymyalgia Rheumatica

United States, Spain, Switzerland, Portugal
University of Zurich
University Hospital, Geneva; University of Bern; Swiss Tropical & Public Health... and other collaborators

Completed

Immunogenicity and Safety of Vaccinations in Immunocompromised Persons

Arthritis, Rheumatoid | Vasculitis | Spondylarthritis

Switzerland
University of Bern
Novartis; University Hospital Inselspital, Berne; Schweizerische Multiple Sklerose... and other collaborators

Recruiting

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Multiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder | CNS Sarcoidosis | CNS Vasculitis | Transverse Myelitis | Rasmussen Encephalitis | Acute Disseminated Encephalomyelitis | Anti-NMDAR Encephalitis | Anti-GAD65 Associated Autoimmune Encephalitis | Anti-AMPAR-1/2 Associated Autoimmune... and other conditions

Switzerland
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
University of Oxford
American College of Rheumatology; The European League Against Rheumatism (EULAR) and other collaborators

Unknown

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS)

Giant Cell Arteritis | Wegener's Granulomatosis | Microscopic Polyangiitis | Polyarteritis Nodosa | Takayasu Arteritis | Churg Strauss Syndrome

Korea, Republic of, United States, Germany, Australia, Japan, Ireland, Belgium, Italy, Denmark, Slovenia, Switzerland, Canada, Argentina, Austria, China, Czech Republic, Egypt, Finland, France, Hungary, India, Mexico, Netherlands, New... and more
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica

Argentina, Estonia, France, Japan, United States, Australia, Belgium, Canada, Germany, Hungary, Israel, Italy, Netherlands, Russian Federation, Switzerland, United Kingdom, Spain
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

Poland, United States, Spain, France, Austria, Belgium, Italy, Romania, Switzerland, Germany, Greece, Netherlands, Australia, Denmark, United Kingdom, Ireland, Bulgaria, Canada, Estonia, Serbia, Sweden
GlaxoSmithKline

Completed

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Thrombosis, Venous

Netherlands, Spain, Germany, Italy, Poland, Russian Federation, France, Israel, Estonia, Hungary, Slovakia, Latvia, Greece, Ukraine, Czech Republic, Switzerland, Bulgaria
Novartis Pharmaceuticals

Active, not recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Belgium, Hungary, Italy, Turkey, Austria, Spain, Switzerland, France, Germany, Israel, Australia, Denmark, Greece, United Kingdom, Guatemala, Bulgaria, Czechia, Estonia, Argentina, Canada, Brazil, Sweden, Finland, Poland, P... and more
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Denmark, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, United Kingdom
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II (ENABLE)

Hereditary Angioedema (HAE)

Germany, Switzerland, Spain, Israel, Italy, Austria, Portugal, Kuwait
BioCryst Pharmaceuticals

Completed

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1)

Hereditary Angioedema (HAE)

Canada, United Kingdom, Germany, Spain, Australia, Hungary, Italy, Austria, North Macedonia, Denmark, Switzerland
Amgen

Recruiting

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Behçet Disease

Spain, United Kingdom, Turkey, France, Greece, Italy, Israel, Switzerland
BioCryst Pharmaceuticals

Completed

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, United Kingdom
Shire
Jerini AG

Completed

EASSI - Evaluation of the Safety of Self-Administration With Icatibant (EASSI)

Hereditary Angioedema

Spain, Argentina, Austria, Denmark, France, Germany, Israel, Italy, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Phase III Study in Refractory Behcet's Disease (SHIELD)

Behcet Disease

India, Turkey, Spain, Germany, Italy, France, Israel, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Switzerland, Taiwan, Tunisia
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
BioCryst Pharmaceuticals

Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

Hereditary Angioedema | Prophylaxis | HAE

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain

Clinical Trials on Urticarial Vasculitis in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations